{"organizations": [], "uuid": "27b60b6e1e8df707b3ad4d8e0b48a7808127d98b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-gsk-says-viiv-healthcare-reports-p/brief-gsk-says-viiv-healthcare-reports-positive-dolutegravir-data-idUSFWN1QN0S9", "country": "US", "domain_rank": 408, "title": "BRIEF-GSK Says ViiV Healthcare Reports Positive Dolutegravir Data", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-05T19:07:00.000+02:00", "replies_count": 0, "uuid": "27b60b6e1e8df707b3ad4d8e0b48a7808127d98b"}, "author": "", "url": "https://www.reuters.com/article/brief-gsk-says-viiv-healthcare-reports-p/brief-gsk-says-viiv-healthcare-reports-positive-dolutegravir-data-idUSFWN1QN0S9", "ord_in_thread": 0, "title": "BRIEF-GSK Says ViiV Healthcare Reports Positive Dolutegravir Data", "locations": [], "entities": {"persons": [{"name": "dolutegravir", "sentiment": "none"}], "locations": [], "organizations": [{"name": "glaxosmithkline plc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "data reuters", "sentiment": "none"}, {"name": "glaxosmithkline plc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 5 (Reuters) - Glaxosmithkline Plc:\n* GLAXOSMITHKLINE PLC - VIIV HEALTHCARE ANNOUNCES POSITIVE NEW DOLUTEGRAVIR DATA FOR TREATMENT OF PEOPLE LIVING WITH HIV CO-INFECTED WITH TUBERCULOSIS\n* GLAXOSMITHKLINE PLC - DOLUTEGRAVIR WHEN ADMINISTERED AT 50MG TWICE-DAILY WITH DUAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, WAS EFFECTIVE\n* GLAXOSMITHKLINE PLC - DOLUTEGRAVIR WAS WELL-TOLERATED IN HIV/TB CO-INFECTED ADULTS RECEIVING RIFAMPIN-BASED TB THERAPY Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-03-05T19:07:00.000+02:00", "crawled": "2018-03-05T19:36:29.005+02:00", "highlightTitle": ""}